Skip to main content

Biostar 2 CVE-2023-33364

HIGH
OS Command Injection (CWE-78)
2023-08-03 cve@mitre.org
8.8
CVSS 3.1 · NVD
Share

Severity by source

NVD PRIMARY
8.8 HIGH
AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

Primary rating from NVD · only source for this CVE.

CVSS VectorNVD

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H
Attack Vector
Network
Attack Complexity
Low
Privileges Required
Low
User Interaction
None
Scope
Unchanged
Confidentiality
High
Integrity
High
Availability
High

Lifecycle Timeline

1
CVE Published
Aug 03, 2023 - 16:15 nvd
HIGH 8.8

DescriptionNVD

An OS Command injection vulnerability exists in Suprema BioStar 2 before V2.9.1, which allows authenticated users to execute arbitrary OS commands on the BioStar 2 server.

AnalysisAI

An OS Command injection vulnerability exists in Suprema BioStar 2 before V2.9.1, which allows authenticated users to execute arbitrary OS commands on the BioStar 2 server. Rated high severity (CVSS 8.8), this vulnerability is remotely exploitable, low attack complexity. No vendor patch available.

Technical ContextAI

This vulnerability is classified as OS Command Injection (CWE-78), which allows attackers to execute arbitrary operating system commands on the host. An OS Command injection vulnerability exists in Suprema BioStar 2 before V2.9.1, which allows authenticated users to execute arbitrary OS commands on the BioStar 2 server. Affected products include: Supremainc Biostar 2.

RemediationAI

No vendor patch is available at time of analysis. Monitor vendor advisories for updates. Avoid passing user input to shell commands. Use language-specific APIs instead of shell execution. Apply strict input validation with allowlists.

Share

CVE-2023-33364 vulnerability details – vuln.today

This site uses cookies essential for authentication and security. No tracking or analytics cookies are used. Privacy Policy